alfuzosin has been researched along with Cardiometabolic Syndrome in 1 studies
alfuzosin: structure given in first source
Cardiometabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study was designed to compare the efficacy of alfuzosin therapy as an alpha-blocker in metabolic syndrome (MetS) and non-MetS patients with moderate lower urinary tract symptoms (LUTS)." | 7.96 | Efficacy of Alfuzosin in Male Patients with Moderate Lower Urinary Tract Symptoms: Is Metabolic Syndrome a Factor Affecting the Outcome? ( Demirtas, A; Keske, M; Sonmez, G; Topaloglu, US, 2020) |
| "The present study was designed to compare the efficacy of alfuzosin therapy as an alpha-blocker in metabolic syndrome (MetS) and non-MetS patients with moderate lower urinary tract symptoms (LUTS)." | 3.96 | Efficacy of Alfuzosin in Male Patients with Moderate Lower Urinary Tract Symptoms: Is Metabolic Syndrome a Factor Affecting the Outcome? ( Demirtas, A; Keske, M; Sonmez, G; Topaloglu, US, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sonmez, G | 1 |
| Topaloglu, US | 1 |
| Keske, M | 1 |
| Demirtas, A | 1 |
1 other study available for alfuzosin and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Efficacy of Alfuzosin in Male Patients with Moderate Lower Urinary Tract Symptoms: Is Metabolic Syndrome a Factor Affecting the Outcome?
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Lower Urinary Tract Symptoms; Male; Metabolic | 2020 |